Onyx settled suit against partner Bayer for a worldwide royalty and U.S. co-promotion rights to Bayer's regorafenib and sold its Japanese royalty rights to Nexavar

Onyx Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$2,293.1m on 10/14/2011 [market cap]

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Bayer AG

Germany / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced